Summary
The role and prognostic value of the tumour suppressor p21/WAF1 expression in epithelial ovarian cancer has not yet been defined. Therefore, the expression of p21/WAF1 was assessed immunohistochemically (IHC) in 316 epithelial ovarian malignancies in relation to p53, cell proliferation and patient survival. p21/WAF1 expression was inversely correlated with p53 and cell proliferation. Low p21/WAF1 expression was significantly associated with high grade of the tumour (P = 0.0005), advanced FIGO stage (P = 0.001) and primary residual tumour (P = 0.0001). Low p21/WAF1 expression was a marker of poor overall survival (P = 0.012). Similarly, p53-positivity and high cell proliferative activity were significant predictors of poor survival in univariate analyses. Moreover, the patients with p21–/p53+ tumours had a poorer overall (P < 0.00005) and recurrence-free (P = 0.0005) survival in univariate analyses, and the p21/p53 expression independently predicted tumour recurrence in Cox’s multivariate analysis. Our results suggest that p21/WAF1 expression is mostly p53-dependent in epithelial ovarian cancer. High p21/WAF1 expression seems to function as a negative cell cycle regulator and as a marker of favourable disease outcome in epithelial ovarian cancer. In addition, the patients with their tumour expressing no or low p21/WAF1 protein but positive for p53 had a notably higher risk of recurrent disease, implicating that these patients might be more prone to treatment failures.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Auer, G., Einhorn, N., Nilsson, B., Silfversward, C. & Sjovall, K. (1996). Biological malignancy grading in early-stage ovarian carcinoma. Acta Oncol 8: 93–98.
Backe, J., Gassel, A. M., Hauber, K., Krebs, S., Bartek, J., Caffier, H., Kreipe, H-H, Muller-Hermelink, H-K & Dietl, J. (1997). p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 16: 361–368.
Barboule, N., Mazars, P., Baldin, V., Vidal, S., Jozan, S., Martel, P. & Valette, A. (1995). Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. Int J Cancer 63: 611–615.
Boring, C. C., Squires, T. S., Tong, T. & Montgomery, S. (1994). Cancer statistics, 1994. CA Cancer J Clin 44: 7–26.
Bukholm, I. K., Nesland, J. M., Karesen, R., Jacobsen, U. & Borresen, A. L. (1997). Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 181: 140–145.
Cancer Committee of the International Federation of Gynecology, Obstetrics (1989). Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 25: 383–385.
Cox, D. R. (1972). Regression models and life tables with discussion. J Stat Soc B 34: 187–192.
Diab, S. G., Yu, Y., Hilsenbeck, S. G., Allred, D. C. & Elledge, R. M. (1997). WAF1/CIP1 protein expression in human breast tumors. Breast Cancer Res Treat 43: 99–103.
Doglioni, C., Pelosio, P., Laurino, L., Macri, E., Meggiolaro, E., Favretti, F. & Barbareschi, M. (1996). p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J Pathol 179: 248–253.
Elbendary, A., Berchuck, A., Davis, P., Havrilesky, I., Bast, R. C. Jr, Iglehart, J. D. & Marks, J. R. (1994). Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5: 1301–1307.
Elbendary, A. A., Cirisano, F. D., Evans, A. C., Davis, P. L., Iglehart, J. D., Marks, J. R. & Berchuk, A. (1996). Relationship between p21 expression and mutation of p53 tumor suppressor gene in normal and malignant ovarian epithelial cells. Clin Cancer Res 2: 1571–1575.
El-Deiry, W. S., Harper, J. W., O’Connor, P. M., Velculescu, V. E., Canman, C. E., Jackman, J., Pietenpol, J. A., Burrell, M., Hill, D. E., Wang, Y., Wiman, K. G., Mercer, W. E., Kastan, M. B., Kohn, K. W., Elledge, S. J., Kinzler, K. W. & Vogelstein, B. (1994). WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54: 1169–1174.
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. & Vogelstein, B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817–825.
El-Deiry, W. S., Tokino, T., Waldman, T., Oliner, J. D., Velculescu, V. E., Burrell, M., Hill, D. E., Healy, E., Rees, J. L., Hamilton, S. R., Kinzler, K. W. & Vogelstein, B. (1995). Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 55: 2910–2919.
Engeland, A., Haldorsen, T., Tretli, S., Hakulinen, T., Horte, L. G., Luostarinen, T., Schou, G., Sigvaldason, H., Storm, H. H. & Tulinius, H. (1995). Prediction of cancer mortality in the Nordic countries up to the years 2000 and 2010, on the basis of relative survival analysis: a collaborative study of five Nordic cancer registries. APMIS Suppl 49: 81–83.
Finnish Cancer Registry (1997). Cancer incidence in Finland 1995. Cancer statistics of the National Research and Development Center for Welfare and Health. Cancer Society of Finland, No. 58
Garzetti, G. G., Ciavattini, A., Gotteri, G., De Nictolis, M., Stramazzotti, D., Lucarini, G. & Biagini, G. (1995). Ki 67 immunostaining (MIB1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol Oncol 56: 169–174.
Gomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N. & Ito, H. (1997). Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. Cancer 79: 2067–2072.
Harada, N., Gansauge, S., Gansauge, F., Gause, H., Shimoyama, S., Imaizumi, T., Mattfield, T., Schoenberger, M. H. & Beger, H. G. (1997). Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in pancreatic cancer. Br J Cancer 76: 299–305.
Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K. & Elledge, S. J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805–816.
Henriksen, R., Strang, P., Wilander, E., Backstrom, T., Tribukait, B. & Oberg, K. (1994). p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry. Gynecol Oncol 53: 301–306.
Herod, J. J., Eliopoulos, A. G., Warwick, J., Niedobitek, G., Young, L. S. & Kerr, D. J. (1996). The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178–2184.
Ito, K., Sasano, H., Matsunaga, G., Sato, S., Yajima, A., Nasim, S. & Garret, C. (1997). Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183: 318–324.
Ito, Y., Kobayashi, T., Takeda, T., Komoike, Y., Wakasugi, E., Tamaki, Y., Tsujimoto, M., Matsuura, N. & Monden, M. (1996). Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. Br J Cancer 74: 1269–1274.
Jiang, H., Lin, J., Su, Z. Z., Collart, F. R., Huberman, E. & Fisher, P. B. (1994). Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene 9: 3397–3406.
Jiang, M., Shao, Z. M., Wu, J., Lu, J. S., Yu, L. M., Yuan, J. D., Han, Q. X., Shen, Z. Z. & Fontana, J. A. (1997). p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. Int J Cancer 74: 529–534.
Kaplan, E. L. & Meier, P. (1958). Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481.
Klemi, P. J., Pylkkänen, L., Kiilholma, P., Kurvinen, K. & Joensuu, H. (1995). p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 76: 1201–1208.
Kohler, M. F., Kerns, B. J., Humphrey, P. A., Marks, J. R., Bast, R. C. Jr & Berchuck, A. (1993a). Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol 81: 643–650.
Kohler, M. F., Marks, J. R., Wiseman, R. W., Jacobs, I. J., Davidoff, A. M., Clarke Pearson, D. L., Soper, J. T., Bast, R. C. Jr & Berchuck, A. (1993b). Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 85: 1513–1519.
Kondo, S., Barna, B. P., Kondo, Y., Tanaka, Y., Casey, G., Liu, J., Morimura, T., Kaakaji, R., Peterson, J. W., Werbel, B. & Barrett, G. H. (1996). WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 13: 1279–1285.
Levesque, M. A., Katsaros, D., Yu, H., Zola, P., Sismondi, P., Giardina, G. & Diamandis, E. P. (1995). Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma. Cancer 75: 1327–1338.
Lukas, J., Groshen, S., Saffari, B., Niu, N., Reles, A., Wen, W. H., Felix, J., Jones, L. A., Hall, F. L. & Press, M. F. (1997). WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. Am J Pathol 150: 167–175.
Marchetti, A., Doglioni, C., Barbareschi, M., Buttita, F., Pellegrini, S., Bertacca, G., Chella, A., Merlo, G., Angeletti, C. A., Palma, P. D. & Bevilacqua, G. (1996). p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 12: 1319–1324.
Marks, J. R., Davidoff, A. M., Kerns, B. J., Humphrey, P. A., Pence, J. C., Dodge, R. K., Clarke Pearson, D. L., Iglehart, J. D., Bast, R. C. Jr & Berchuck, A. (1991). Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51: 2979–2984.
Mateo, M. S., Saez, A. L., Sanchez-Beato, M., Garcia, P., Sanchez-Verde, L., Martinez, J. C., Orradre, J. L. & Piris, M. A. (1997). Expression of p21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53. J Clin Pathol 50: 645–653.
Michieli, P., Chedid, M., Lin, D., Pierce, J. H., Mercer, W. E. & Givol, D. (1994). Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391–3395.
Ogawa, M., Maeda, K., Onoda, N., Chung, Y. S. & Sowa, M. (1997). Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. Br J Cancer 75: 1617–1620.
Palazzo, J. P., Mercer, W. E., Kovatich, A. J. & McHugh, M. (1997). Immunohistochemical localization of p21WAF1/CIP1 in normal, hyperplastic, and neoplastic uterine tissues. Hum Pathol 28: 60–66.
Parker, S. L., Tong, T., Bolden, S. & Wingo, P. A. (1997). Cancer statistics, 1997. CA Cancer J Clin 47: 5–27.
Serov, S. F., Scully, R. & Sobin, L. H. (1973). Histological typing of ovarian tumours. International Histological Classification of Tumors, no 9: Geneva: WHO
Sheikh, M. S., Li, X. S., Chen, J. C., Shao, Z. M., Ordonez, J. V. & Fontana, J. A. (1994). Mechanisms of regulation of WAF1/Cip1 gene expression in human breast carcinoma: role of p53-dependent and independent signal transduction pathways. Oncogene 9: 3407–3415.
Shigemasa, K., Hu, C., West, C. M., Moon, S. H., Parham, G. P., Parmley, T. H., Korourian, S., Baker, V. V. & O’Brien, T. J. (1997). p21: a monitor of p53 dysfunction in ovarian neoplasia. Int J Gynecol Cancer 7: 296–303.
Wakasugi, E., Kobayashi, T., Tamaki, Y., Ito, Y., Miyashiro, I., Komoike, Y., Takeda, T., Shin, E., Takatsuka, Y., Kikkawa, N., Monden, T. & Monden, M. (1997). p21 (Waf1/Cip1) and p53 protein expression in breast cancer. Am J Clin Pathol 107: 684–691.
van der Zee, A. G., Hollema, H., Suurmeijer, A. J., Krans, M., Sluiter, W. J., Willemse, P. H., Aalders, J. G. & de Vries, E. G. (1995). Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13: 70–78.
Wan, M., Zweizig, S., D’Ablaing, G., Zheng, J., Velicescu, M. & Dubeau, L. (1994). Three distinct regions of chromosome 6 are targets of loss of heterozygosity in human ovarian carcinomas. Int J Oncol 5: 1043–1048.
Werness, B. A., Jobe, J. S., DiCioccio, R. A. & Piver, M. S. (1997a). Expression of the p53 induced tumor suppressor p21waf1/cip1 in ovarian carcinomas: correlation with p53 and Ki-67 immunohistochemistry. Int J Gyn Pathol 16: 149–155.
Werness, B. A., Wang, H-Q, Chance, J. & Goldstein, D. J. (1997b). p53-independent expression of p21waf1/cip1 in preinvasive and invasive squamous neoplasms of the uterine cervix. Mod Pathol 10: 578–584.
Zhang, W., Grasso, L., McClain, C. D., Gambel, A. M., Cha, Y., Travali, S., Deisseroth, A. B. & Mercer, W. E. (1995). p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res 55: 668–674.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Anttila, M., Kosma, VM., Hongxiu, J. et al. p21/WAF1 expression as related to p53, cell proliferation and prognosis in epithelial ovarian cancer. Br J Cancer 79, 1870–1878 (1999). https://doi.org/10.1038/sj.bjc.6690298
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690298
Keywords
This article is cited by
-
Cellular senescence in cancer: clinical detection and prognostic implications
Journal of Experimental & Clinical Cancer Research (2022)
-
A Study of Expression and Significance of p53 in Malignant Ovarian Surface Epithelial Tumours
Indian Journal of Gynecologic Oncology (2021)
-
Up-regulation of miR-95-3p in hepatocellular carcinoma promotes tumorigenesis by targeting p21 expression
Scientific Reports (2016)
-
Rab14 is overexpressed in ovarian cancers and promotes ovarian cancer proliferation through Wnt pathway
Tumor Biology (2016)
-
High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation
Cancer Cell International (2015)